{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T02:00:10Z","timestamp":1793412010726,"version":"4.5.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T00:00:00Z","timestamp":1770422400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"vor","delay-in-days":32,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pediatr"],"DOI":"10.1186\/s12887-026-06595-y","type":"journal-article","created":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T02:58:00Z","timestamp":1770433080000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Safety and efficacy of omalizumab in children aged 6 to 11 years with asthma: a systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.1186","volume":"26","author":[{"given":"Yi","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuiyun","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongli","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxue","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,7]]},"reference":[{"key":"6595_CR1","unstructured":"Global Initiative for Asthma Global Strategy for Asthma Management and Prevention. 2023. http:\/\/www.ginasthma.org\/."},{"key":"6595_CR2","doi-asserted-by":"publisher","unstructured":"Ioniuc I, Miron I, Lupu VV, Starcea IM, Azoicai A, Alexoae M, et al. Challenges in the pharmacotherapeutic management of pediatric asthma. Pharmaceuticals (Basel Switzerland). 2022;15(12). https:\/\/doi.org\/10.3390\/ph15121581.","DOI":"10.3390\/ph15121581"},{"issue":"21","key":"6595_CR3","doi-asserted-by":"publisher","first-page":"2226","DOI":"10.1056\/NEJMra054308","volume":"355","author":"W Eder","year":"2006","unstructured":"Eder W, Ege MJ, von Mutius E. The asthma epidemic. N Engl J Med. 2006;355(21):2226\u201335. https:\/\/doi.org\/10.1056\/NEJMra054308.","journal-title":"N Engl J Med"},{"key":"6595_CR4","doi-asserted-by":"publisher","unstructured":"Nucera E, Rizzi A, Agros\u00ec C, Lohmeyer FM, Inchingolo R. Lung function Tests, quality of life and telemedicine: three windows on the multifaceted world of asthma in adolescents. Child (Basel Switzerland). 2022;9(4). https:\/\/doi.org\/10.3390\/children9040476.","DOI":"10.3390\/children9040476"},{"issue":"6","key":"6595_CR5","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.4110\/in.2022.22.e45","volume":"22","author":"S Sim","year":"2022","unstructured":"Sim S, Choi Y, Park HS. Immunologic basis of type 2 biologics for severe asthma. Immune Netw. 2022;22(6):e45. https:\/\/doi.org\/10.4110\/in.2022.22.e45.","journal-title":"Immune Netw"},{"issue":"2","key":"6595_CR6","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1097\/aci.0000000000000880","volume":"23","author":"S Saxena","year":"2023","unstructured":"Saxena S, Rosas-Salazar C, Fitzpatrick A, Bacharier LB. Biologics and severe asthma in children. Curr Opin Allergy Clin Immunol. 2023;23(2):111\u20138. https:\/\/doi.org\/10.1097\/aci.0000000000000880.","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"6595_CR7","doi-asserted-by":"publisher","unstructured":"Patel VH, Thannir S, Dhanani M, Augustine I, Sandeep SL, Mehadi A et al. Current limitations and recent advances in the management of Asthma. Disease-a-month: DM. 2023; 69(7): 101483. https:\/\/doi.org\/10.1016\/j.disamonth.2022.101483","DOI":"10.1016\/j.disamonth.2022.101483"},{"key":"6595_CR8","doi-asserted-by":"publisher","unstructured":"Chen CY, Wu KH, Guo BC, Lin WY, Chang YJ, Wei CW, et al. Personalized medicine in severe asthma: from biomarkers to biologics. Int J Mol Sci. 2023;25(1). https:\/\/doi.org\/10.3390\/ijms25010182.","DOI":"10.3390\/ijms25010182"},{"issue":"9","key":"6595_CR9","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1080\/17476348.2018.1505507","volume":"12","author":"C Ozdemir","year":"2018","unstructured":"Ozdemir C, Kucuksezer UC, Akdis M, Akdis CA. The concepts of asthma endotypes and phenotypes to guide current and novel treatment strategies. Expert Rev Respir Med. 2018;12(9):733\u201343. https:\/\/doi.org\/10.1080\/17476348.2018.1505507.","journal-title":"Expert Rev Respir Med"},{"issue":"8 Pt 2","key":"6595_CR10","doi-asserted-by":"publisher","first-page":"S6","DOI":"10.1164\/ajrccm.164.supplement_1.2103025","volume":"164","author":"ES Schulman","year":"2001","unstructured":"Schulman ES. Development of a monoclonal anti-immunoglobulin E antibody (omalizumab) for the treatment of allergic respiratory disorders. Am J Respir Crit Care Med. 2001;164(8 Pt 2):S6\u201311. https:\/\/doi.org\/10.1164\/ajrccm.164.supplement_1.2103025.","journal-title":"Am J Respir Crit Care Med"},{"issue":"11","key":"6595_CR11","doi-asserted-by":"publisher","first-page":"4187","DOI":"10.4049\/jimmunol.1601476","volume":"197","author":"T Kawakami","year":"2016","unstructured":"Kawakami T, Blank U. From IgE to Omalizumab. J Immunol (Baltimore Md: 1950). 2016;197(11):4187\u201392. https:\/\/doi.org\/10.4049\/jimmunol.1601476.","journal-title":"J Immunol (Baltimore Md: 1950)"},{"issue":"8","key":"6595_CR12","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1164\/rccm.201701-0120OC","volume":"196","author":"A Esquivel","year":"2017","unstructured":"Esquivel A, Busse WW, Calatroni A, Togias AG, Grindle KG, Bochkov YA, et al. Effects of Omalizumab on rhinovirus Infections, Illnesses, and exacerbations of asthma. Am J Respir Crit Care Med. 2017;196(8):985\u201392. https:\/\/doi.org\/10.1164\/rccm.201701-0120OC.","journal-title":"Am J Respir Crit Care Med"},{"issue":"11","key":"6595_CR13","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1056\/NEJMoa1009705","volume":"364","author":"WW Busse","year":"2011","unstructured":"Busse WW, Morgan WJ, Gergen PJ, Mitchell HE, Gern JE, Liu AH, et al. Randomized trial of Omalizumab (anti-IgE) for asthma in inner-city children. N Engl J Med. 2011;364(11):1005\u201315. https:\/\/doi.org\/10.1056\/NEJMoa1009705.","journal-title":"N Engl J Med"},{"issue":"1","key":"6595_CR14","doi-asserted-by":"publisher","first-page":"100737","DOI":"10.1016\/j.waojou.2022.100737","volume":"16","author":"AN Sitek","year":"2023","unstructured":"Sitek AN, Li JT, Pongdee T. Risks and safety of biologics: A practical guide for allergists. World Allergy Organ J. 2023;16(1):100737. https:\/\/doi.org\/10.1016\/j.waojou.2022.100737.","journal-title":"World Allergy Organ J"},{"key":"6595_CR15","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ (Clinical Res ed). 2021;372:n71. https:\/\/doi.org\/10.1136\/bmj.n71.","journal-title":"BMJ (Clinical Res ed)"},{"key":"6595_CR16","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins JP, Altman DG, G\u00f8tzsche PC, J\u00fcni P, Moher D, Oxman AD, et al. The Cochrane collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ (Clinical Res ed). 2011;343:d5928. https:\/\/doi.org\/10.1136\/bmj.d5928.","journal-title":"BMJ (Clinical Res ed)"},{"issue":"2","key":"6595_CR17","doi-asserted-by":"publisher","first-page":"E36","DOI":"10.1542\/peds.108.2.e36","volume":"108","author":"H Milgrom","year":"2001","unstructured":"Milgrom H, Berger W, Nayak A, Gupta N, Pollard S, McAlary M, et al. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). Pediatrics. 2001;108(2):E36. https:\/\/doi.org\/10.1542\/peds.108.2.e36.","journal-title":"Pediatrics"},{"issue":"4","key":"6595_CR18","doi-asserted-by":"publisher","first-page":"e308","DOI":"10.1542\/peds.113.4.e308","volume":"113","author":"PE Silkoff","year":"2004","unstructured":"Silkoff PE, Romero FA, Gupta N, Townley RG, Milgrom H. Exhaled nitric oxide in children with asthma receiving xolair (omalizumab), a monoclonal anti-immunoglobulin E antibody. Pediatrics. 2004;113(4):e308\u2013312. https:\/\/doi.org\/10.1542\/peds.113.4.e308.","journal-title":"Pediatrics"},{"issue":"6","key":"6595_CR19","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1016\/j.jaci.2009.09.021","volume":"124","author":"B Lanier","year":"2009","unstructured":"Lanier B, Bridges T, Kulus M, Taylor AF, Berhane I, Vidaurre CF. Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma. J Allergy Clin Immunol. 2009;124(6):1210\u20136. https:\/\/doi.org\/10.1016\/j.jaci.2009.09.021.","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"6595_CR20","doi-asserted-by":"publisher","first-page":"182","DOI":"10.15586\/aei.v51i4.926","volume":"51","author":"F Chen","year":"2023","unstructured":"Chen F, Liang L, Chu FF, Lu C, Xu C. Effects of Omalizumab combined with Budesonide formoterol on clinical efficacy, pulmonary function, immune function, and adverse reactions in children with moderate and severe allergic asthma. Allergol Immunopathol (Madr). 2023;51(4):182\u20138. https:\/\/doi.org\/10.15586\/aei.v51i4.926.","journal-title":"Allergol Immunopathol (Madr)"},{"issue":"3","key":"6595_CR21","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1080\/1744666x.2020.1724089","volume":"16","author":"K Jackson","year":"2020","unstructured":"Jackson K, Bahna SL. Hypersensitivity and adverse reactions to biologics for asthma and allergic diseases. Expert Rev Clin Immunol. 2020;16(3):311\u20139. https:\/\/doi.org\/10.1080\/1744666x.2020.1724089.","journal-title":"Expert Rev Clin Immunol"},{"issue":"6","key":"6595_CR22","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1016\/j.jaci.2007.09.032","volume":"120","author":"L Cox","year":"2007","unstructured":"Cox L, Platts-Mills TA, Finegold I, Schwartz LB, Simons FE, Wallace DV. American academy of Allergy, asthma & immunology\/American college of Allergy, asthma and immunology joint task force report on omalizumab-associated anaphylaxis. J Allergy Clin Immunol. 2007;120(6):1373\u20137. https:\/\/doi.org\/10.1016\/j.jaci.2007.09.032.","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"6595_CR23","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1111\/pai.13484","volume":"32","author":"A Nieto Garc\u00eda","year":"2021","unstructured":"Nieto Garc\u00eda A, Garriga-Baraut T, Plaza Mart\u00edn AM, Nieto Cid M, Torres Borrego J, Folqu\u00e9 Gim\u00e9nez MDM, et al. Omalizumab outcomes for up to 6 years in pediatric patients with severe persistent allergic asthma. Pediatr Allergy Immunol. 2021;32(5):980\u201391. https:\/\/doi.org\/10.1111\/pai.13484.","journal-title":"Pediatr Allergy Immunol"},{"key":"6595_CR24","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.rmed.2017.07.013","volume":"130","author":"D Di Bona","year":"2017","unstructured":"Di Bona D, Fiorino I, Taurino M, Frisenda F, Minenna E, Pasculli C, et al. Long-term real-life safety of Omalizumab in patients with severe uncontrolled asthma: A nine-year study. Respir Med. 2017;130:55\u201360. https:\/\/doi.org\/10.1016\/j.rmed.2017.07.013.","journal-title":"Respir Med"},{"key":"6595_CR25","doi-asserted-by":"publisher","unstructured":"Galletta F, Caminiti L, Lugar\u00e0 C, Foti Randazzese S, Barraco P, D\u2019Amico F, et al., et al. Long-Term safety of Omalizumab in children with asthma and\/or chronic spontaneous urticaria: A 4-Year prospective study in real life. J Pers Med. 2023;13. https:\/\/doi.org\/10.3390\/jpm13071068.","DOI":"10.3390\/jpm13071068"},{"issue":"12","key":"6595_CR26","doi-asserted-by":"publisher","first-page":"3149","DOI":"10.1016\/j.jaip.2022.08.013","volume":"10","author":"F Shakuntulla","year":"2022","unstructured":"Shakuntulla F, Chiarella SE. Safety of biologics for atopic diseases during pregnancy. J Allergy Clin Immunol Pract. 2022;10(12):3149\u201355. https:\/\/doi.org\/10.1016\/j.jaip.2022.08.013.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"8","key":"6595_CR27","doi-asserted-by":"publisher","first-page":"843","DOI":"10.3109\/02770903.2012.717659","volume":"49","author":"RW Dal Negro","year":"2012","unstructured":"Dal Negro RW, Tognella S, Pradelli L. A 36-month study on the cost\/utility of add-on Omalizumab in persistent difficult-to-treat atopic asthma in Italy. J Asthma: Official J Association Care Asthma. 2012;49(8):843\u20138. https:\/\/doi.org\/10.3109\/02770903.2012.717659.","journal-title":"J Asthma: Official J Association Care Asthma"},{"issue":"1","key":"6595_CR28","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.aller.2012.07.006","volume":"42","author":"T Vieira","year":"2014","unstructured":"Vieira T, de Oliveira JF. Da Gra\u00e7a Castel-Branco M. Short and long-term quality of life and asthma control with Omalizumab therapy in a real life setting in Portugal. Allergol Immunopathol (Madr). 2014;42(1):3\u201310. https:\/\/doi.org\/10.1016\/j.aller.2012.07.006.","journal-title":"Allergol Immunopathol (Madr)"},{"issue":"3","key":"6595_CR29","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1183\/09031936.00008115","volume":"46","author":"A Deschildre","year":"2015","unstructured":"Deschildre A, Marguet C, Langlois C, Pin I, Ritti\u00e9 JL, Derelle J, et al. Real-life long-term Omalizumab therapy in children with severe allergic asthma. Eur Respir J. 2015;46(3):856\u20139. https:\/\/doi.org\/10.1183\/09031936.00008115.","journal-title":"Eur Respir J"},{"issue":"6","key":"6595_CR30","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1185\/03007991003771338","volume":"26","author":"M Kulus","year":"2010","unstructured":"Kulus M, H\u00e9bert J, Garcia E, Fowler Taylor A, Fernandez Vidaurre C, Blogg M. Omalizumab in children with inadequately controlled severe allergic (IgE-mediated) asthma. Curr Med Res Opin. 2010;26(6):1285\u201393. https:\/\/doi.org\/10.1185\/03007991003771338.","journal-title":"Curr Med Res Opin"},{"issue":"8","key":"6595_CR31","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.1016\/j.jaip.2020.03.033","volume":"8","author":"SJ Szefler","year":"2020","unstructured":"Szefler SJ, Casale TB, Haselkorn T, Yoo B, Ortiz B, Kattan M, et al. Treatment benefit with Omalizumab in children by indicators of asthma severity. J Allergy Clin Immunol Pract. 2020;8(8):2673\u2013e26802673. https:\/\/doi.org\/10.1016\/j.jaip.2020.03.033.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"5","key":"6595_CR32","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1111\/all.13678","volume":"74","author":"A Deschildre","year":"2019","unstructured":"Deschildre A, Roussel J, Drumez E, Abou-Taam R, Rames C, Le Roux P, et al. Omalizumab discontinuation in children with severe allergic asthma: an observational real-life study. Allergy. 2019;74(5):999\u20131003. https:\/\/doi.org\/10.1111\/all.13678.","journal-title":"Allergy"},{"issue":"5","key":"6595_CR33","doi-asserted-by":"publisher","first-page":"439","DOI":"10.5114\/ada.2017.71109","volume":"34","author":"A Sztafi\u0144ska","year":"2017","unstructured":"Sztafi\u0144ska A, Jerzy\u0144ska J, Stelmach W, Woicka-Kolejwa K, Stelmach I. Quality of life in asthmatic children and their caregivers after two-year treatment with omalizumab, a real-life study. Postepy Dermatologii I Alergologii. 2017;34(5):439\u201347. https:\/\/doi.org\/10.5114\/ada.2017.71109.","journal-title":"Postepy Dermatologii I Alergologii"},{"issue":"2","key":"6595_CR34","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.anai.2019.11.016","volume":"124","author":"WW Busse","year":"2020","unstructured":"Busse WW, Humbert M, Haselkorn T, Ortiz B, Trzaskoma BL, Stephenson P, et al. Effect of Omalizumab on lung function and eosinophil levels in adolescents with moderate-to-severe allergic asthma. Annals of allergy, asthma & immunology. Asthma Immunol. 2020;124(2):190\u20136. https:\/\/doi.org\/10.1016\/j.anai.2019.11.016. official publication of the American College of Allergy.","journal-title":"Asthma Immunol"},{"key":"6595_CR35","doi-asserted-by":"publisher","unstructured":"Galletta F, Passanisi S, Foti Randazzese S, Licari A, Manti S. Real-life evaluation of biologics in pediatric severe asthma using core outcome measures for severe asthma. Ann Allergy Asthma Immunol. 2025;135(590\u2013591). https:\/\/doi.org\/10.1016\/j.anai.2025.07.027.","DOI":"10.1016\/j.anai.2025.07.027"},{"issue":"3","key":"6595_CR36","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1097\/aci.0000000000000161","volume":"15","author":"CE Baena-Cagnani","year":"2015","unstructured":"Baena-Cagnani CE, Teijeiro A, Canonica GW. Four-year follow-up in children with moderate\/severe uncontrolled asthma after withdrawal of a 1-year Omalizumab treatment. Curr Opin Allergy Clin Immunol. 2015;15(3):267\u201371. https:\/\/doi.org\/10.1097\/aci.0000000000000161.","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"6595_CR37","doi-asserted-by":"publisher","unstructured":"Humbert M, Bourdin A, Taill\u00e9 C, Kamar D, Thonnelier C, Lajoinie A, et al. Real-life Omalizumab exposure and discontinuation in a large nationwide population-based study of paediatric and adult asthma patients. Eur Respir J. 2022;60(5). https:\/\/doi.org\/10.1183\/13993003.03130-2021.","DOI":"10.1183\/13993003.03130-2021"}],"container-title":["BMC Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12887-026-06595-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12887-026-06595-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12887-026-06595-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T10:57:26Z","timestamp":1773226646000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12887-026-06595-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,7]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["6595"],"URL":"https:\/\/doi.org\/10.1186\/s12887-026-06595-y","relation":{},"ISSN":["1471-2431"],"issn-type":[{"value":"1471-2431","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,7]]},"assertion":[{"value":"12 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"\u200bThis meta-analysis strictly adhered to the Declaration of Helsinki, with all included studies providing documented ethical approval from institutional review boards. Participant confidentiality was maintained throughout the process, utilizing only anonymized data. Additionally, the systematic review has been registered with PROSPERO under the registration number CRD42024531092.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"208"}}